Pila Pharma AB (publ) (STO:PILA)

Market Cap	81.54M -0.5%
Revenue (ttm)	1.13M +42.6%
Net Income	-17.00M
EPS	-0.49
Shares Out	45.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,432
Average Volume	90,344
Open	1.705
Previous Close	1.785
Day's Range	1.705 - 1.835
52-Week Range	1.024 - 3.930
Beta	-0.32
RSI	53.75
Earnings Date	Aug 27, 2026

About Pila Pharma AB

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PILA

Financial Performance

In 2025, Pila Pharma AB's revenue was 1.13 million, an increase of 42.65% compared to the previous year's 789,889. Losses were -17.00 million, 51.3% more than in 2024.